View Item 

Show simple item record

Construct Validity of the Patient‐Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis
dc.contributor.authorNagaraja, Viveken_US
dc.contributor.authorHays, Ron D.en_US
dc.contributor.authorKhanna, Puja P.en_US
dc.contributor.authorSpiegel, Brennan M. R.en_US
dc.contributor.authorChang, Linen_US
dc.contributor.authorMelmed, Gil Y.en_US
dc.contributor.authorBolus, Rogeren_US
dc.contributor.authorKhanna, Dineshen_US
dc.date.accessioned2014-11-04T16:35:45Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-11-04T16:35:45Z
dc.date.issued2014-11en_US
dc.identifier.citationNagaraja, Vivek; Hays, Ron D.; Khanna, Puja P.; Spiegel, Brennan M. R.; Chang, Lin; Melmed, Gil Y.; Bolus, Roger; Khanna, Dinesh (2014). "Construct Validity of the Patient‐Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosis ." Arthritis Care & Research 66(11): 1725-1730.en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/109333
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherMcGraw‐Hillen_US
dc.titleConstruct Validity of the Patient‐Reported Outcomes Measurement Information System Gastrointestinal Symptom Scales in Systemic Sclerosisen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/109333/1/acr22337.pdf
dc.identifier.doi10.1002/acr.22337en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceCampbell DT, Fiske DW. Convergent and discriminant validation by the multitrait‐multimethod matrix. Psychol Bull 1959; 56: 81 – 105.en_US
dc.identifier.citedreferenceKhanna D, Furst DE, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Minimally important differences of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. J Rheumatol 2011; 38: 1920 – 4.en_US
dc.identifier.citedreferenceKhanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the University of California, Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument. Arthritis Rheum 2009; 61: 1257 – 63.en_US
dc.identifier.citedreferenceCella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, et al. The Patient‐Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007; Suppl 1: S3 – 11.en_US
dc.identifier.citedreferenceKhanna D, Krishnan E, Dewitt EM, Khanna PP, Spiegel B, Hays RD. The future of measuring patient‐reported outcomes in rheumatology: Patient‐Reported Outcomes Measurement Information System (PROMIS). Arthritis Care Res (Hoboken) 2011; Suppl 11: S486 – 90.en_US
dc.identifier.citedreferenceSpiegel BM, Khanna D, Bolus R, Agarwal N, Khanna P, Chang L. Understanding gastrointestinal distress: a framework for clinical practice. Am J Gastroenterol 2011; 106: 380 – 5.en_US
dc.identifier.citedreferenceSpiegel BM, Hays RD, Bolus R, Melmed GY, Chang L, Whitman C, et al. Development of the NIH Patient Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol 2014. In press.en_US
dc.identifier.citedreferenceHays RD, Liu H, Spritzer K, Cella D. Item response theory analyses of physical functioning items in the medical outcomes study. Med Care 2007; Suppl 1: S32 – 8.en_US
dc.identifier.citedreferenceReeve BB, Hays RD, Bjorner JB, Cook KF, Crane PK, Teresi JA, et al. Psychometric evaluation and calibration of health‐related quality of life item banks: plans for the Patient‐Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; Suppl 1: S22 – 31.en_US
dc.identifier.citedreferenceFries JF, Cella D, Rose M, Krishnan E, Bruce B. Progress in assessing physical function in arthritis: PROMIS short forms and computerized adaptive testing. J Rheumatol 2009; 36: 2061 – 6.en_US
dc.identifier.citedreferenceDeWalt DA, Rothrock N, Yount S, Stone AA, Group PC. Evaluation of item candidates: the PROMIS qualitative item review. Med Care 2007; Suppl 1: S12 – 21.en_US
dc.identifier.citedreferenceBae S, Allanore Y, Coustet B, Maranian P, Khanna D. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium gastrointestinal tract instrument. Clin Exp Rheumatol 2011; Suppl 65: S15 – 21.en_US
dc.identifier.citedreferenceSubcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581 – 90.en_US
dc.identifier.citedreferenceNunnally JC. Psychometric theory. 2nd ed. New York: McGraw‐Hill; 1978.en_US
dc.identifier.citedreferenceKhanna D, Maranian P, Rothrock N, Cella D, Gershon R, Khanna PP, et al. Feasibility and construct validity of PROMIS and “legacy” instruments in an academic scleroderma clinic. Value Health 2012; 15: 128 – 34.en_US
dc.identifier.citedreferenceAkesson A, Wollheim FA. Organ manifestations in 100 patients with progressive systemic sclerosis: a comparison between the CREST syndrome and diffuse scleroderma. Brit J Rheumatol 1989; 28: 281 – 6.en_US
dc.identifier.citedreferenceFrech T, Hays RD, Maranian P, Clements PJ, Furst DE, Khanna D. Prevalence and correlates of sleep disturbance in systemic sclerosis: results from the UCLA scleroderma quality of life study. Rheumatology (Oxford) 2011; 50: 1280 – 7.en_US
dc.identifier.citedreferenceNtoumazios SK, Voulgari PV, Potsis K, Koutis E, Tsifetaki N, Assimakopoulos DA. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem. Semin Arthritis Rheum 2006; 36: 173 – 81.en_US
dc.identifier.citedreferenceSallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006; 23: 691 – 712.en_US
dc.identifier.citedreferenceYarze JC, Varga J, Stampfl D, Castell DO, Jimenez SA. Esophageal function in systemic sclerosis: a prospective evaluation of motility and acid reflux in 36 patients. Am J Gastroenterol 1993; 88: 870 – 6.en_US
dc.identifier.citedreferenceFries J, Rose M, Krishnan E. The PROMIS of better outcome assessment: responsiveness, floor and ceiling effects, and internet administration. J Rheumatol 2011; 38: 1759 – 64.en_US
dc.identifier.citedreferenceRose M, Bjorner JB, Becker J, Fries JF, Ware JE. Evaluation of a preliminary physical function item bank supported the expected advantages of the Patient‐Reported Outcomes Measurement Information System (PROMIS). J Clin Epidemiol 2008; 61: 17 – 33.en_US
dc.identifier.citedreferenceSpiegel BM. Patient‐reported outcomes in gastroenterology: clinical and research applications. J Neurogastroenterol Motil 2013; 19: 137 – 48.en_US
dc.identifier.citedreferenceKhanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol 2013; 25: 700 – 6.en_US
dc.identifier.citedreferenceKhanna D, Tsevat J. Health‐related quality of life: an introduction. Am J Manag Care 2007; Suppl 9: S218 – 23.en_US
dc.identifier.citedreferenceLock G, Holstege A, Lang B, Scholmerich J. Gastrointestinal manifestations of progressive systemic sclerosis. Am J Gastroenterol 1997; 92: 763 – 71.en_US
dc.identifier.citedreferenceSjogren RW. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994; 37: 1265 – 82.en_US
dc.identifier.citedreferenceBodukam V, Hays RD, Maranian P, Furst DE, Seibold JR, Impens A, et al. Association of gastrointestinal involvement and depressive symptoms in patients with systemic sclerosis. Rheumatology (Oxford) 2011; 50: 330 – 4.en_US
dc.identifier.citedreferenceKulig M, Leodolter A, Vieth M, Schulte E, Jaspersen D, Labenz J, et al. Quality of life in relation to symptoms in patients with gastro‐oesophageal reflux disease: an analysis based on the ProGERD initiative. Aliment Pharmacol Ther 2003; 18: 767 – 76.en_US
dc.identifier.citedreferenceBae S, Allanore Y, Furst DE, Bodukam V, Coustet B, Morgaceva O, et al. Associations between a scleroderma‐specific gastrointestinal instrument and objective tests of upper gastrointestinal involvements in systemic sclerosis. Clin Exp Rheumatol 2013; Suppl 76: 57 – 63.en_US
dc.identifier.citedreferenceBaron M, Hudson M, Steele R, Lo E, and the Canadian Scleroderma Research Group. Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument version 2.0 for systemic sclerosis. J Rheumatol 2011; 38: 1925 – 30.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
acr22337.pdf
Size:
78.87KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.